FibroBiologics (FBLG) Research & Development (2023 - 2026)

FibroBiologics (FBLG) has reported Research & Development for 4 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 18.77% year-over-year to $1.7 million; the trailing twelve-month figure through Jun 2026 stood at $8.2 million (up 28.28% YoY), and the FY2025 full-year result was $7.4 million, up 64.45% from the prior year.
• Research & Development eased to $1.7 million in Q2 2026 per FBLG's latest filing, from $3.0 million in the prior quarter.
• Across five years, Research & Development topped out at $3.0 million in Q1 2026 and bottomed at $478000.0 in Q1 2023.
• Historically, Research & Development has averaged $1.3 million across 4 years, with a median of $1.1 million in 2024.
• The widest YoY moves for Research & Development: up 129.93% in 2025, down 41.22% in 2025.
• Over 4 years, Research & Development stood at $773000.0 in 2023, then surged by 75.42% to $1.4 million in 2024, then sank by 41.22% to $797000.0 in 2025, then surged by 108.03% to $1.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $1.7 million, $3.0 million, and $797000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.